In the face of tariffs, FDA-approved drug manufacturing deals are shifting to Europe
Last year saw the largest fall in US contract manufacturing (CM) deals for FDA-approved drugs in five years. Despite the highest import tariffs in modern history on EU pharmaceuticals, GlobalData’s Deals database revealed that biopharma companies, including US-based firms, are increasingly outsourcing drug manufacturing for the US market to European-based facilities rather than turning to … Read more